EVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evaxion A/S (EVAX) is not a strong buy for a beginner, long-term investor at this moment. Despite positive analyst ratings and a promising AI-driven platform, the company's financial performance is weak, with no revenue in the latest quarter and a significant net loss. Additionally, the technical indicators and trading signals do not suggest a compelling entry point. Without clear positive catalysts or strong financial growth, it's better to hold off on investing in EVAX right now.
The MACD is slightly positive but contracting, RSI is neutral at 38.719, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 3.595, with resistance levels at 4.429 and 4.686. Overall, the technical indicators suggest a neutral to slightly bearish sentiment.
Analysts have provided positive ratings with price targets ranging from $9 to $10, citing the company's AI-driven platform and promising melanoma asset.
The company reported no revenue in Q4 2025, and EPS dropped significantly (-96.77% YoY). The stock also experienced a regular market decline of -2.97% and a pre-market dip of -0.27%. There is no recent news or significant trading activity to support a bullish sentiment.
In Q4 2025, revenue dropped to 0 (-100% YoY), net income improved to -$5,918,000 (+63.08% YoY), and EPS fell to -0.01 (-96.77% YoY). Gross margin remained at 100%. The financials indicate a lack of revenue generation and ongoing losses, despite some improvement in net income.
Analysts have a Buy rating on EVAX with price targets of $9 and $10. They highlight the company's AI-driven platform and its potential in oncology and infectious disease vaccines. However, there has been a slight reduction in the price target from $11 to $9 by Lake Street.
